Photo of Raymond T. Chung,  MD

Raymond T. Chung, MD

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 724-7562
Fax: (617) 726-5895

Raymond T. Chung, MD

Massachusetts General Hospital


  • Associate Professor, Medicine, Harvard Medical School
  • Director of Hepatology, Medicine Service, Massachusetts General Hospital


Research Abstract

Hepatocellular carcinoma (HCC) is now a firmly established and largely incurable complication of chronic HCV, and its prevalence in this country will continue to grow as a large cohort of patients infected decades ago comes to clinical attention. While most cases appear to arise in the setting of chroinic inflammation, cirrhosis, and regeneration, the pathogenesis of HCV-related HCC remains unknown. Transgenic mouse models permit the opportunity to examine the effects of selective expression of viral proteins. A recent report has suggested that transgenic mice expressing the HCV core protein alone develop HCC. We have created a transgenic mouse model that successfully expresses HCV core as well as the two envelope glycoproteins (core-E1-E2); however, these animals do not develop liver disease. The basis for these observed differences is unknown.

We are exploring the contributions of three major arms to HCV-related HCC: (1) viral protein expression; (2) host genetic predisposition; and (3) the host immune response. To accomplish this, we wil use novel transgenic mouse models to explore the direct contribution of both HCV structural and nonstructural proteins to transformation. We have also crossed our transgenic HCV structural protein mice with NF2 +/- heterozygotes that spontaneously develop HCC in a large portion of aging animals. This cross will allow us to "read out" the contribution of viral protein expression to HCC development (by increased frequency or acceleration of HCC formation), as well as to determine whether HCV-induced HCC requires a host genetic predisposition. We are also creating a novel, inducible transgenic model that expresses the full length HCV polyprotein (and which replicates HCV RNA in transfection studies) to explore the contribution of activation of the host immune system to HCV-related hepatocarcinogenesis. Finally, we are using the core mouse to examine the longitudinal events in gene expression to determine which host genes contribute to disease progression in this model. Together, these models will help dissect the factors responsible for this devastating complication of chronic HCV infection.


Powered by Harvard Catalyst
  • Goto K, Kato N, Chung RT. Anti-hepatocellular carcinoma properties of the anti-alcoholism drug disulfiram discovered to enzymatically inhibit the AMPK-related kinase SNARK in vitro. 2016. PubMed
  • Salloum S, Holmes JA, Jindal R, Bale SS, Brisac C, Alatrakchi N, Lidofsky A, Kruger AJ, Fusco DN, Luther J, Schaefer EA, Lin W, Yarmush ML, Chung RT. Exposure to human immunodeficiency virus/hepatitis C virus in hepatic and stellate cell lines reveals cooperative profibrotic transcriptional activation between viruses and cell types. Hepatology 2016. PubMed
  • Gane E, Kowdley KV, Pound D, Stedman CA, Davis M, Etzkorn K, Gordon SC, Bernstein D, Everson G, Rodriguez-Torres M, Tsai N, Khalid O, Yang JC, Lu S, Dvory-Sobol H, Stamm LM, Brainard DM, McHutchison JG, Tong M, Chung RT, Beavers K, Poulos JE, Kwo PY, Nguyen MH. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-label, Phase 2 Trial. Gastroenterology 2016. PubMed
  • Brisac C, Salloum S, Yang V, Schaefer EA, Holmes JA, Chevaliez S, Hong J, Carlton-Smith C, Alatrakchi N, Kruger A, Lin W, Chung RT. IQGAP2 is a novel interferon-alpha antiviral effector gene acting non-conventionally through the NF-κB pathway. J Hepatol 2016. PubMed
  • Holmes JA, Chung RT. Viral hepatitis: HCV compartmentalization in HCC: driver, passenger or both? Nat Rev Gastroenterol Hepatol 2016; 13:254-6. PubMed
  • DePeralta DK, Wei L, Ghoshal S, Schmidt B, Lauwers GY, Lanuti M, Chung RT, Tanabe KK, Fuchs BC. Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis. Cancer 2016; 122:1216-27. PubMed
  • Mueller JL, King LY, Johnson KB, Gao T, Nephew LD, Kothari D, Simpson MA, Zheng H, Wei L, Corey KE, Misdraji J, Lee JH, Lin MV, Gogela NA, Fuchs BC, Tanabe KK, Gordon FD, Curry MP, Chung RT. Impact of EGF, IL28B, and PNPLA3 polymorphisms on the outcome of allograft hepatitis C: a multicenter study. Clin Transplant 2016; 30:452-60. PubMed
  • Chhatwal J, Wang X, Ayer T, Kabiri M, Chung RT, Hur C, Donohue JM, Roberts MS, Kanwal F. Hepatitis C Disease Burden in the United States in the Era of Oral Direct-Acting Antivirals. Hepatology 2016. PubMed
  • Zhou C, York SR, Chen JY, Pondick JV, Motola DL, Chung RT, Mullen AC. Long noncoding RNAs expressed in human hepatic stellate cells form networks with extracellular matrix proteins. Genome Med 2016; 8:31. PubMed
  • Rajbhandari R, Chung RT. Treatment of Hepatitis B: A Concise Review. Clin Transl Gastroenterol 2016; 7:e190. PubMed
  • Chusri P, Kumthip K, Hong J, Zhu C, Duan X, Jilg N, Fusco DN, Brisac C, Schaefer EA, Cai D, Peng LF, Maneekarn N, Lin W, Chung RT. HCV induces transforming growth factor β1 through activation of endoplasmic reticulum stress and the unfolded protein response. Sci Rep 2016; 6:22487. PubMed
  • Della-Torre E, Feeney E, Deshpande V, Mattoo H, Mahajan V, Kulikova M, Wallace ZS, Carruthers M, Chung RT, Pillai S, Stone JH. B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related disease. Ann Rheum Dis 2015. PubMed
  • Everson GT, Towner WJ, Davis MN, Wyles DL, Nahass RG, Thuluvath PJ, Etzkorn K, Hinestrosa F, Tong M, Rabinovitz M, McNally J, Brainard DM, Han L, Doehle B, McHutchison JG, Morgan T, Chung RT, Tran TT. Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial. Ann Intern Med 2015; 163:818-26. PubMed
  • Khalili M, Lombardero M, Chung RT, Terrault NA, Ghany MG, Kim WR, Lau D, Lisker-Melman M, Sanyal A, Lok AS, . Diabetes and prediabetes in patients with hepatitis B residing in North America. Hepatology 2015. PubMed
  • Simon RE, Pearson SD, Hur C, Chung RT. Tackling the hepatitis C cost problem: A test case for tomorrow's cures. Hepatology 2015. PubMed
  • Baumert TF, Verrier ER, Nassal M, Chung RT, Zeisel MB. Host-targeting agents for treatment of hepatitis B virus infection. Curr Opin Virol 2015; 14:41-6. PubMed
  • Simon TG, Chung RT. The new hepatitis C virus bottleneck: Can delaying therapy be justified? Hepatology 2015. PubMed
  • Feeney ER, Chung RT, Yazdanpanah Y. Current guidelines and prioritizing treatment of hepatitis C virus in HIV-infected patients. Curr Opin HIV AIDS 2015; 10:323-9. PubMed
  • Li DK, Chung RT. Impact of hepatitis C virus eradication on hepatocellular carcinogenesis. Cancer 2015. PubMed
  • Feeney ER, Chung RT. The Polymerase Chain Reaction: Essential for the Development of Curative Therapy for Hepatitis C. Dig Dis Sci 2015; 60:2232-5. PubMed
  • King LY, Canasto-Chibuque C, Johnson KB, Yip S, Chen X, Kojima K, Deshmukh M, Venkatesh A, Tan PS, Sun X, Villanueva A, Sangiovanni A, Nair V, Mahajan M, Kobayashi M, Kumada H, Iavarone M, Colombo M, Fiel MI, Friedman SL, Llovet JM, Chung RT, Hoshida Y. A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Gut 2015. PubMed
  • Zhu C, Xiao F, Hong J, Wang K, Liu X, Cai D, Fusco DN, Zhao L, Jeong SW, Brisac C, Chusri P, Schaefer EA, Zhao H, Peng LF, Lin W, Chung RT. EFTUD2 Is a Novel Innate Immune Regulator Restricting Hepatitis C Virus Infection through the RIG-I/MDA5 Pathway. J Virol 2015; 89:6608-18. PubMed
  • Xu GJ, Kula T, Xu Q, Li MZ, Vernon SD, Ndung'u T, Ruxrungtham K, Sanchez J, Brander C, Chung RT, O'Connor KC, Walker B, Larman HB, Elledge SJ. Viral immunology. Comprehensive serological profiling of human populations using a synthetic human virome. Science 2015; 348:aaa0698. PubMed
  • Cheng D, Zhang L, Yang G, Zhao L, Peng F, Tian Y, Xiao X, Chung RT, Gong G. Hepatitis C virus NS5A drives a PTEN-PI3K/Akt feedback loop to support cell survival. Liver Int 2015. PubMed
  • Lin W, Zhu C, Hong J, Zhao L, Jilg N, Fusco DN, Schaefer EA, Brisac C, Liu X, Peng LF, Xu Q, Chung RT. The spliceosome factor SART1 exerts its anti-HCV action through mRNA splicing. J Hepatol 2015. PubMed
  • Gogela NA, Lin MV, Wisocky JL, Chung RT. Enhancing our understanding of current therapies for hepatitis C virus (HCV). Curr HIV/AIDS Rep 2015; 12:68-78. PubMed
  • Delgado-Borrego A, Gonzalez-Peralta RP, Raza R, Negre B, Goodman ZD, Jonas MM, Chung RT, Ludwig DA, . Correlates of adiponectin in hepatitis C-infected children: the importance of body mass index. J Pediatr Gastroenterol Nutr 2015. PubMed
  • Curry MP, Forns X, Chung RT, Terrault NA, Brown R, Fenkel JM, Gordon F, O'Leary J, Kuo A, Schiano T, Everson G, Schiff E, Befeler A, Gane E, Saab S, McHutchison JG, Subramanian GM, Symonds WT, Denning J, McNair L, Arterburn S, Svarovskaia E, Moonka D, Afdhal N. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 2014. PubMed
  • Lin MV, King LY, Chung RT. Hepatitis C virus-associated cancer. Annu Rev Pathol 2015; 10:345-70. PubMed
  • Mueller JL, Feeney ER, Zheng H, Misdraji J, Kruger AJ, Alatrakchi N, King LY, Gelrud L, Corey KE, Chung RT. Circulating Soluble CD163 is Associated with Steatohepatitis and Advanced Fibrosis in Nonalcoholic Fatty Liver Disease. Clin Transl Gastroenterol 2015; 6:e114. PubMed
  • Abramson JS, Chung RT. Optimal antiviral prophylaxis against hepatitis B reactivation in patients receiving rituximab-based chemotherapy for lymphoma. JAMA 2014; 312:2505-7. PubMed
  • Motola DL, Caravan P, Chung RT, Fuchs BC. Noninvasive Biomarkers of Liver Fibrosis: Clinical Applications and Future Directions. Curr Pathobiol Rep 2014; 2:245-256. PubMed
  • Hoshida Y, Fuchs BC, Bardeesy N, Baumert TF, Chung RT. Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J Hepatol 2014; 61:S79-90. PubMed
  • Rajbhandari R, Chung RT. Screening for hepatitis B virus infection: a public health imperative. Ann Intern Med 2014. PubMed
  • Chen JY, Feeney ER, Chung RT. HCV and HIV co-infection: mechanisms and management. Nat Rev Gastroenterol Hepatol 2014. PubMed
  • deLemos AS, Chung RT. Hepatitis C treatment: an incipient therapeutic revolution. Trends Mol Med 2014. PubMed
  • Li H, Yang X, Yang G, Hong Z, Zhou L, Yin P, Xiao Y, Chen L, Chung RT, Zhang L. Hepatitis C virus NS5A hijacks ARFGAP1 to maintain a phosphatidylinositol 4-phosphate-enriched microenvironment. J Virol 2014. PubMed
  • Wu Y, Johnson KB, Roccaro G, Lopez J, Zheng H, Muiru A, Ufere N, Rajbhandari R, Kattan O, Chung RT. Poor adherence to AASLD guidelines for chronic hepatitis B Management and treatment in a large academic medical center. Am J Gastroenterol 2014. PubMed
  • Schmidt WN, Nelson DR, Pawlotsky JM, Sherman KE, Thomas DL, Chung RT. Direct-acting antiviral agents and the path to interferon independence. Clin Gastroenterol Hepatol 2014; 12:728-37. PubMed
  • Jilg N, Lin W, Hong J, Schaefer EA, Wolski D, Meixong J, Goto K, Brisac C, Chusri P, Fusco DN, Chevaliez S, Luther J, Kumthip K, Urban TJ, Peng LF, Lauer GM, Chung RT. Kinetic differences in the induction of interferon stimulated genes by interferon-α and interleukin 28B are altered by infection with hepatitis C virus. Hepatology 2014; 59:1250-61. PubMed
  • Fofana I, Jilg N, Chung RT, Baumert TF. Entry inhibitors and future treatment of hepatitis C. Antiviral Res 2014; 104:136-42. PubMed
  • Hong J, Yuan Y, Wang J, Liao Y, Zou R, Zhu C, Li B, Liang Y, Huang P, Wang Z, Lin W, Zeng Y, Dai JL, Chung RT. Expression of variant isoforms of the tyrosine kinase SYK determines the prognosis of hepatocellular carcinoma. Cancer Res 2014; 74:1845-56. PubMed
  • Kroy DC, Ciuffreda D, Cooperrider JH, Tomlinson M, Hauck GD, Aneja J, Berger C, Wolski D, Carrington M, Wherry EJ, Chung RT, Tanabe KK, Elias N, Freeman GJ, de Kruyff RH, Misdraji J, Kim AY, Lauer GM. Liver environment and HCV replication affect human T-cell phenotype and expression of inhibitory receptors. Gastroenterology 2014; 146:550-61. PubMed
  • King LY, Johnson KB, Zheng H, Wei L, Gudewicz T, Hoshida Y, Corey KE, Ajayi T, Ufere N, Baumert TF, Chan AT, Tanabe KK, Fuchs BC, Chung RT. Host genetics predict clinical deterioration in HCV-related cirrhosis. PLoS ONE 2014; 9:e114747. PubMed
  • Jang JY, Kim SJ, Cho EK, Jeong SW, Park EJ, Lee WC, Lee SH, Kim SG, Kim YS, Kim HS, Kim BS, Lin W, Chung RT. TRAIL enhances apoptosis of human hepatocellular carcinoma cells sensitized by hepatitis C virus infection: therapeutic implications. PLoS ONE 2014; 9:e98171. PubMed
  • Zator ZA, Chung RT. After the cure: management of HCV after achievement of SVR. Curr HIV/AIDS Rep 2013; 10:428-35. PubMed
  • Nakahira K, Kyung SY, Rogers AJ, Gazourian L, Youn S, Massaro AF, Quintana C, Osorio JC, Wang Z, Zhao Y, Lawler LA, Christie JD, Meyer NJ, Mc Causland FR, Waikar SS, Waxman AB, Chung RT, Bueno R, Rosas IO, Fredenburgh LE, Baron RM, Christiani DC, Hunninghake GM, Choi AM. Circulating mitochondrial DNA in patients in the ICU as a marker of mortality: derivation and validation. PLoS Med. 2014; 10:e1001577; discussion e1001577. PubMed
  • Rottiers V, Obad S, Petri A, McGarrah R, Lindholm MW, Black JC, Sinha S, Goody RJ, Lawrence MS, deLemos AS, Hansen HF, Whittaker S, Henry S, Brookes R, Najafi-Shoushtari SH, Chung RT, Whetstine JR, Gerszten RE, Kauppinen S, Näär AM. Pharmacological inhibition of a microRNA family in nonhuman primates by a seed-targeting 8-mer antimiR. Sci Transl Med 2013; 5:212ra162. PubMed
  • Schaefer EA, Chung RT. HCV and host lipids: an intimate connection. Semin Liver Dis 2013; 33:358-68. PubMed
  • Goto K, Lin W, Zhang L, Jilg N, Shao RX, Schaefer EA, Zhao H, Fusco DN, Peng LF, Kato N, Chung RT. The AMPK-related kinase SNARK regulates hepatitis C virus replication and pathogenesis through enhancement of TGF-β signaling. J Hepatol 2013; 59:942-8. PubMed
  • Bai H, Chen T, Ming J, Sun H, Cao P, Fusco DN, Chung RT, Chorev M, Jin Q, Aktas BH. Dual activators of protein kinase R (PKR) and protein kinase R-like kinase PERK identify common and divergent catalytic targets. Chembiochem 2013; 14:1255-62. PubMed
  • Fusco DN, Brisac C, John SP, Huang YW, Chin CR, Xie T, Zhao H, Jilg N, Zhang L, Chevaliez S, Wambua D, Lin W, Peng L, Chung RT, Brass AL. A genetic screen identifies interferon-α effector genes required to suppress hepatitis C virus replication. Gastroenterology 2013. PubMed
  • Hoshida Y, Villanueva A, Sangiovanni A, Sole M, Hur C, Andersson KL, Chung RT, Gould J, Kojima K, Gupta S, Taylor B, Crenshaw A, Gabriel S, Minguez B, Iavarone M, Friedman SL, Colombo M, Llovet JM, Golub TR. Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology 2013; 144:1024-30. PubMed
  • Duggal P, Thio CL, Wojcik GL, Goedert JJ, Mangia A, Latanich R, Kim AY, Lauer GM, Chung RT, Peters MG, Kirk GD, Mehta SH, Cox AL, Khakoo SI, Alric L, Cramp ME, Donfield SM, Edlin BR, Tobler LH, Busch MP, Alexander G, Rosen HR, Gao X, Abdel-Hamid M, Apps R, Carrington M, Thomas DL. Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med 2013; 158:235-45. PubMed
  • Ding Q, Lee YK, Schaefer EA, Peters DT, Veres A, Kim K, Kuperwasser N, Motola DL, Meissner TB, Hendriks WT, Trevisan M, Gupta RM, Moisan A, Banks E, Friesen M, Schinzel RT, Xia F, Tang A, Xia Y, Figueroa E, Wann A, Ahfeldt T, Daheron L, Zhang F, Rubin LL, Peng LF, Chung RT, Musunuru K, Cowan CA. A TALEN genome-editing system for generating human stem cell-based disease models. Cell Stem Cell 2013; 12:238-51. PubMed
  • Shao RX, Zhang L, Hong Z, Goto K, Cheng D, Chen WC, Jilg N, Kumthip K, Fusco DN, Peng LF, Chung RT. SOCS1 abrogates IFN's antiviral effect on hepatitis C virus replication. Antiviral Res 2013; 97:101-7. PubMed
  • Rutherford A, King LY, Lee WM, Chung RT. Reply: To PMID 22885329. Gastroenterology 2012; 144:e26. PubMed
  • Scaiewicz V, Nahmias A, Chung RT, Mueller T, Tirosh B, Shibolet O. CCAAT/enhancer-binding protein homologous (CHOP) protein promotes carcinogenesis in the DEN-induced hepatocellular carcinoma model. PLoS ONE 2013; 8:e81065. PubMed
  • Watanabe T, Hiasa Y, Tokumoto Y, Hirooka M, Abe M, Ikeda Y, Matsuura B, Chung RT, Onji M. Protein kinase R modulates c-Fos and c-Jun signaling to promote proliferation of hepatocellular carcinoma with hepatitis C virus infection. PLoS ONE 2013; 8:e67750. PubMed
  • Jeong SW, Jang JY, Chung RT. Hepatitis C virus and hepatocarcinogenesis. Clin Mol Hepatol 2013; 18:347-56. PubMed
  • Delgado-Borrego A, Smith L, Jonas MM, Hall CA, Negre B, Jordan SH, Ogrodowicz M, Raza R, Ludwig DA, Miller T, Lipshultz SE, Gonzalez-Peralta R, Chung RT. Expected and actual case ascertainment and treatment rates for children infected with hepatitis C in Florida and the United States: epidemiologic evidence from statewide and nationwide surveys. J Pediatr 2012; 161:915-21. PubMed
  • Sahani DV, Agarwal S, Chung RT. The double-edged sword of functional liver imaging. Radiology 2012; 264:621-3. PubMed
  • Huang YW, Chung RT. Management of hepatitis B reactivation in patients receiving cancer chemotherapy. Therap Adv Gastroenterol 2012; 5:359-70. PubMed
  • Kumthip K, Chusri P, Jilg N, Zhao L, Fusco DN, Zhao H, Goto K, Cheng D, Schaefer EA, Zhang L, Pantip C, Thongsawat S, O'Brien A, Peng LF, Maneekarn N, Chung RT, Lin W. Hepatitis C virus NS5A disrupts STAT1 phosphorylation and suppresses type I interferon signaling. J Virol 2012; 86:8581-91. PubMed
  • Rodgers MA, Villareal VA, Schaefer EA, Peng LF, Corey KE, Chung RT, Yang PL. Lipid metabolite profiling identifies desmosterol metabolism as a new antiviral target for hepatitis C virus. J Am Chem Soc 2012; 134:6896-9. PubMed
  • Goldwasser J, Cohen PY, Lin W, Kitsberg D, Balaguer P, Polyak SJ, Chung RT, Yarmush ML, Nahmias Y. Naringenin inhibits the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanism. J Hepatol 2011. PubMed
  • Abu Dayyeh BK, Yang M, Fuchs BC, Karl DL, Yamada S, Sninsky JJ, O'Brien TR, Dienstag JL, Tanabe KK, Chung RT, . A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology 2011. PubMed
  • Fusco DN, Chung RT. New protease inhibitors for HCV--help is on the way. J Hepatol 2011. PubMed
  • Han SH, Reddy KR, Keeffe EB, Soldevila-Pico C, Gish R, Chung RT, Degertekin B, Lok A, . Clinical outcomes of liver transplantation for HBV-related hepatocellular carcinoma: data from the NIH HBV OLT study. Clin Transplant 2011; 25:E152-62. PubMed
  • Chen JY, Chung RT. Can we use the "C" word with confidence? Cure for chronic hepatitis C. Gastroenterology 2011; 140:766-8. PubMed
  • Zhang L, Jilg N, Shao RX, Lin W, Fusco DN, Zhao H, Goto K, Peng LF, Chen WC, Chung RT. IL28B inhibits Hepatitis C virus replication through the JAK-STAT pathway. J Hepatol 2010. PubMed
  • Chung RT, Poordad FF, Hassanein T, Zhou X, Lentz E, Prabhakar A, Di Bisceglie AM. Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C. Hepatology 2010; 52:1906-14. PubMed
  • Sherman KE, Andersen JW, Butt AA, Umbleja T, Alston B, Koziel MJ, Peters MG, Sulkowski M, Goodman ZD, Chung RT, . Sustained Long-Term Antiviral Maintenance Therapy in HCV/HIV-Coinfected Patients (SLAM-C). J Acquir Immune Defic Syndr 2010. PubMed
  • Kim AY, Kuntzen T, Timm J, Nolan BE, Baca MA, Reyor LL, Berical AC, Feller AJ, Johnson KL, Schulze Zur Wiesch J, Robbins GK, Chung RT, Walker BD, Carrington M, Allen TM, Lauer GM. Spontaneous control of HCV is associated with the expression of HLA-B*57 and preservation of targeted epitopes. Gastroenterology 2010. PubMed
  • Moriguchi H, Chung RT, Mihara M, Sato C. Generation of human induced pluripotent stem cells from liver progenitor cells by only small molecules. Hepatology 2010; 52:1169; author reply 1169-70. PubMed
  • Jang JY, Chung RT. New treatments for chronic hepatitis C. Korean J Hepatol 2010; 16:263-77. PubMed
  • Méndez-Navarro J, Chirino RA, Corey KE, Gorospe EC, Zheng H, Morán S, Chung RT, Dehesa-Violante M. A Randomized Controlled Trial of Double Versus Triple Therapy with Amantadine for Genotype 1 Chronic Hepatitis C in Latino Patients. Dig Dis Sci 2010; 55:2629-35. PubMed
  • Méndez-Navarro J, Corey KE, Zheng H, Barlow LL, Jang JY, Lin W, Zhao H, Shao RX, McAfee SL, Chung RT. Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy. Liver Int 2010. PubMed
  • Delgado-Borrego A, Healey D, Negre B, Christofi M, Sabharwal S, Ludwig DA, Chung RT, Jonas MM. Influence of body mass index on outcome of pediatric chronic hepatitis C virus infection. J Pediatr Gastroenterol Nutr 2010; 51:191-7. PubMed
  • Shao RX, Zhang L, Peng LF, Sun E, Chung WJ, Jang JY, Tsai WL, Hyppolite G, Chung RT. Suppressor of cytokine signaling 3 suppresses hepatitis C virus replication in an mTOR-dependent manner. J Virol 2010; 84:6060-9. PubMed
  • Contreras AM, Ochoa-Jiménez RJ, Celis A, Méndez C, Olivares L, Rebolledo CE, Hernandez-Lugo I, Aguirre-Zavala AI, Jiménez-Méndez R, Chung RT. High antibody level: an accurate serologic marker of viremia in asymptomatic people with hepatitis C infection. Transfusion 2010; 50:1335-43. PubMed
  • Lin W, Tsai WL, Shao RX, Wu G, Peng LF, Barlow LL, Chung WJ, Zhang L, Zhao H, Jang JY, Chung RT. HCV regulates TGF-beta1 production through the generation of reactive oxygen species in an NFkappaB-dependent manner. Gastroenterology 2010; 138:2509-18, 2518.e1. PubMed
  • Monto A, Schooley RT, Lai JC, Sulkowski MS, Chung RT, Pawlotsky JM, McHutchison JG, Jacobson IM. Lessons From HIV Therapy Applied to Viral Hepatitis Therapy: Summary of a Workshop. Am J Gastroenterol 2010; 105:989-1004; quiz 988, 1005. PubMed
  • Delgado-Borrego A, Jordan SH, Negre B, Healey D, Lin W, Kamegaya Y, Christofi M, Ludwig DA, Lok AS, Chung RT, . Reduction of Insulin Resistance With Effective Clearance of Hepatitis C Infection: Results From the HALT-C Trial. Clin Gastroenterol Hepatol 2010; 8:458-62. PubMed
  • Chung RT. Reaping the early harvest of the genomics revolution. Gastroenterology 2010; 138:1653-4. PubMed
  • Moriguchi H, Chung RT, Sato C. An indicator for evaluating the risk of cancerous transformations of human induced pluripotent stem cells. Hepatology 2010; 51:1085-6. PubMed
  • Sherman KE, Soriano V, Chung RT. Human immunodeficiency virus and liver disease: Conference proceedings. Hepatology 2010; 51:1046-54. PubMed
  • Moriguchi H, Chung RT, Sato C. An identification of novel therapy for human hepatocellular carcinoma by using human induced pluripotent stem cells. Hepatology 2010; 51:1090-1. PubMed
  • Moriguchi H, Chung RT, Sato C. Tumorigenicity of human induced pluripotent stem cells depends on the balance of gene expression between p21 and p53. Hepatology 2010; 51:1088-9. PubMed
  • Sherman KE, Rouster SD, Stanford S, Blackard JT, Shire N, Koziel M, Peters M, Chung RT, . Hepatitis C virus (HCV) quasispecies complexity and selection in HCV/HIV-coinfected subjects treated with interferon-based regimens. J Infect Dis 2010; 201:712-9. PubMed
  • Méndez-Navarro J, Chirino RA, Corey KE, Gorospe EC, Zheng H, Morán S, Juarez JA, Chung RT, Dehesa-Violante M. Erratum to: A Randomized Controlled Trial of Double Versus Triple Therapy with Amantadine for Genotype 1 Chronic Hepatitis C in Latino Patients. Dig Dis Sci 2010. PubMed
  • Moriguchi H, Chung RT, Sato C. An identification of the novel combination therapy for hepatitis C virus 1b infection by using a replicon system and human induced pluripotent stem cells. Hepatology 2009; 51:351-2. PubMed
  • Moriguchi H, Chung RT, Sato C. New translational research on novel drugs for hepatitis C virus 1b infection by using a replicon system and human induced pluripotent stem cells. Hepatology 2009; 51:344-5; author reply 345. PubMed
  • King LY, Chung RT. When treating cancer, please don't forget hepatitis B. Oncologist 2010; 15:826-9. PubMed
  • Schiødt FV, Chung RT, Schilsky ML, Hay JE, Christensen E, Lee WM, . Outcome of acute liver failure in the elderly. Liver Transpl 2009; 15:1481-7. PubMed
  • McGovern BH, Birch CE, Bowen MJ, Reyor LL, Nagami EH, Chung RT, Kim AY. Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria. Clin Infect Dis 2009; 49:1051-60. PubMed
  • Deshpande V, Sainani NI, Chung RT, Pratt DS, Mentha G, Rubbia-Brandt L, Lauwers GY. IgG4-associated cholangitis: a comparative histological and immunophenotypic study with primary sclerosing cholangitis on liver biopsy material. Mod Pathol 2009; 22:1287-95. PubMed
  • Corey KE, Servoss JC, Casson DR, Kim AY, Robbins GK, Franzini J, Twitchell K, Loomis SC, Abraczinskas DR, Terella AM, Dienstag JL, Chung RT. Pilot study of postexposure prophylaxis for hepatitis C virus in healthcare workers. Infect Control Hosp Epidemiol 2009; 30:1000-5. PubMed
  • Corey KE, Kane E, Munroe C, Barlow LL, Zheng H, Chung RT. Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology 2009; 50:1030-7. PubMed
  • McGovern BH, Nagami EH, Birch CE, Bowen MJ, Reyor LL, Chung RT, Kim AY. Rate of sustained virologic response in relation to baseline hepatitis C virus (HCV) RNA level and rapid virologic clearance in persons with acute HCV infection. J Infect Dis 2009; 200:877-81. PubMed
  • Kim AY, Chung RT. Coinfection with HIV-1 and HCV--a one-two punch. Gastroenterology 2009; 137:795-814. PubMed
  • Everhart JE,Lok AS,Kim HY,Morgan TR,Lindsay KL,Chung RT,Bonkovsky HL,Ghany MG. Weight Related Effects on Disease Progression in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial. Gastroenterology 2009; 137:549-57. PubMed
  • Zúñiga J, Romero V, Azocar J, Terreros D, Vargas-Rojas MI, Torres-García D, Jiménez-Alvarez L, Vargas-Alarcón G, Granados-Montiel J, Husain Z, Chung RT, Alper CA, Yunis EJ. Protective KIR-HLA interactions for HCV infection in intravenous drug users. Mol Immunol 2009; 46:2723-7. PubMed
  • Welzel TM,Morgan TR,Bonkovsky HL,Naishadham D,Pfeiffer RM,Wright EC,Hutchinson AA,Crenshaw AT,Bashirova A,Carrington M,Dotrang M,Sterling RK,Lindsay KL,Fontana RJ,Lee WM,Di Bisceglie AM,Ghany MG,Gretch DR,Chanock SJ,Chung RT,O'Brien TR. Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 2009; 49:1847-58. PubMed
  • Nelson AL, Millington TM, Sahani D, Chung RT, Bauer C, Hertl M, Warshaw AL, Conrad C. Hepatic portal venous gas: the ABCs of management. Arch Surg 2009; 144:575-81; discussion 581. PubMed
  • Lok AS,Everhart JE,Chung RT,Kim HY,Everson GT,Hoefs JC,Greenson JK,Sterling RK,Lindsay KL,Lee WM,Di Bisceglie AM,Bonkovsky HL,Ghany MG,Morishima C. Evolution of hepatic steatosis in patients with advanced hepatitis C: Results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology 2009; 49:1828-37. PubMed
  • Corey KE,Shah N,Misdraji J,Abu Dayyeh BK,Zheng H,Bhan AK,Chung RT. The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver Int 2009; 29:748-53. PubMed
  • Andersson KL,Chung RT. Monitoring during and after antiviral therapy for hepatitis B. Hepatology 2009; 49:S166-73. PubMed
  • Tai AW,Chung RT. Racial differences in response to interferon-based antiviral therapy for hepatitis C virus infection: a hardwiring issue? J Infect Dis 2009; 199:1101-3. PubMed
  • Shire NJ,Rao MB,Succop P,Buncher CR,Andersen JA,Butt AA,Chung RT,Sherman KE. Improving noninvasive methods of assessing liver fibrosis in patients with hepatitis C virus/human immunodeficiency virus co-infection. Clin Gastroenterol Hepatol 2009; 7:471-80, 480.e1-2. PubMed
  • Kim KA,Lin W,Tai AW,Shao RX,Weinberg E,De Sa Borges CB,Bhan AK,Zheng H,Kamegaya Y,Chung RT. Hepatic SOCS3 expression is strongly associated with non-response to therapy and race in HCV and HCV/HIV infection. J Hepatol 2009; 50:705-11. PubMed
  • Tai AW,Benita Y,Peng LF,Kim SS,Sakamoto N,Xavier RJ,Chung RT. A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microbe 2009; 5:298-307. PubMed
  • Tai AW,Chung RT. Treatment failure in hepatitis C: mechanisms of non-response. J Hepatol 2008; 50:412-20. PubMed
  • Kuntzen T,Timm J,Berical A,Lennon N,Berlin AM,Young SK,Lee B,Heckerman D,Carlson J,Reyor LL,Kleyman M,McMahon CM,Birch C,Schulze Zur Wiesch J,Ledlie T,Koehrsen M,Kodira C,Roberts AD,Lauer GM,Rosen HR,Bihl F,Cerny A,Spengler U,Liu Z,Kim AY,Xing Y,Schneidewind A,Madey MA,Fleckenstein JF,Park VM,Galagan JE,Nusbaum C,Walker BD,Lake-Bakaar GV,Daar ES,Jacobson IM,Gomperts ED,Edlin BR,Donfield SM,Chung RT,Talal AH,Marion T,Birren BW,Henn MR,Allen TM. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 2008; 48:1769-78. PubMed
  • Andersson KL,Salomon JA,Goldie SJ,Chung RT. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2008; 6:1418-24. PubMed
  • McGovern BH,Abu Dayyeh BK,Chung RT. Avoiding therapeutic pitfalls: the rational use of specifically targeted agents against hepatitis C infection. Hepatology 2008; 48:1700-12. PubMed
  • Sabharwal S,Delgado-Borrego A,Chung RT. Extrahepatic hepatitis C virus after transplantation: diabetes and renal dysfunction. Liver Transpl 2008; 14 Suppl 2:S51-7. PubMed
  • Morgan TR,Lambrecht RW,Bonkovsky HL,Chung RT,Naishadham D,Sterling RK,Fontana RJ,Lee WM,Ghany MG,Wright EC,O'Brien TR. DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J Hepatol 2008; 49:548-56. PubMed
  • Miller JC,Hahn PF,Chung RT,Thrall JH,Lee SI. Screening for hepatocellular carcinoma in cirrhotic patients. J Am Coll Radiol 2008; 5:1012-4. PubMed
  • Martin NM,Abu Dayyeh BK,Chung RT. Anabolic steroid abuse causing recurrent hepatic adenomas and hemorrhage. World J Gastroenterol 2008; 14:4573-5. PubMed
  • Hiasa Y, Kuzuhara H, Tokumoto Y, Konishi I, Yamashita N, Matsuura B, Michitaka K, Chung RT, Onji M. Hepatitis C virus replication is inhibited by 22beta-methoxyolean-12-ene-3beta, 24(4beta)-diol (ME3738) through enhancing interferon-beta. Hepatology 2008; 48:59-69. PubMed
  • Abu Dayyeh BK,Chung RT. Broadly neutralizing antibodies against hepatitis C virus: new hope for immunization? Gastroenterology 2008; 134:2184-6. PubMed
  • Xia Y, Babitt JL, Sidis Y, Chung RT, Lin HY. Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin. Blood 2008; 111:5195-204. PubMed
  • Nahmias Y, Goldwasser J, Casali M, van Poll D, Wakita T, Chung RT, Yarmush ML. Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. Hepatology 2008; 47:1437-45. PubMed
  • Romero V, Azocar J, Zuniga J, Clavijo OP, Terreros D, Gu X, Husain Z, Chung RT, Amos C, Yunis EJ. Interaction of NK inhibitory receptor genes with HLA-C and MHC class II alleles in Hepatitis C virus infection outcome. Mol Immunol 2008; 45:2429-36. PubMed
  • Swan T, Chung RT. Development of novel agents for the treatment of hepatitis C virus. Hepatology 2008; 47:1426. PubMed
  • Tanabe KK, Lemoine A, Finkelstein DM, Kawasaki H, Fujii T, Chung RT, Lauwers GY, Kulu Y, Muzikansky A, Kuruppu D, Lanuti M, Goodwin JM, Azoulay D, Fuchs BC. Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA 2008; 299:53-60. PubMed
  • Chung RT, Gale M Jr, Polyak SJ, Lemon SM, Liang TJ, Hoofnagle JH. Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop. Hepatology 2007; 47:306-20. PubMed
  • O'Leary JG, Zachary K, Misdraji J, Chung RT. De novo autoimmune hepatitis during immune reconstitution in an HIV-infected patient receiving highly active antiretroviral therapy. Clin Infect Dis 2008; 46:e12-4. PubMed
  • Corey KE, Chung RT. Treating difficult-to-treat hepatitis C virus infection: we may still need to push the ribavirin envelope. Gastroenterology 2007; 133:2062-3. PubMed
  • Kuntzen T, Timm J, Berical A, Lewis-Ximenez LL, Jones A, Nolan B, Schulze zur Wiesch J, Li B, Schneidewind A, Kim AY, Chung RT, Lauer GM, Allen TM. Viral sequence evolution in acute hepatitis C virus infection. J Virol 2007; 81:11658-68. PubMed
  • Kang M, Chung RT. The role of early viral decline in the treatment of hepatitis C in HIV-1-coinfected persons. J Acquir Immune Defic Syndr 2007; 46:371-3. PubMed
  • Kim AY, Chung RT. Sex, drugs, and hepatitis C virus in men who have sex with men: evidence for permucosal transmission. Gastroenterology 2007; 133:1734-6; discussion 1736-7. PubMed
  • Peng LF, Kim SS, Matchacheep S, Lei X, Su S, Lin W, Runguphan W, Choe WH, Sakamoto N, Ikeda M, Kato N, Beeler AB, Porco JA Jr, Schreiber SL, Chung RT. Identification of novel epoxide inhibitors of hepatitis C virus replication using a high-throughput screen. Antimicrob Agents Chemother 2007; 51:3756-9. PubMed
  • Tai AW, Chung RT. The hepatitis C virus plot thickens: enter claudin-1. Gastroenterology 2007; 133:1041-2. PubMed
  • Pekow JR, Bhan AK, Zheng H, Chung RT. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer 2007; 109:2490-6. PubMed
  • Fontana RJ, Sanyal AJ, Mehta S, Doherty MC, Neuschwander-Tetri BA, Everson GT, Kahn JA, Malet PF, Sheikh MY, Chung RT, Ghany MG, Gretch DR,. Portal Hypertensive Gastropathy in Chronic Hepatitis C Patients with Bridging Fibrosis and Compensated Cirrhosis: Results from the HALT-C Trial. Am J Gastroenterol 2006; 101:983-92. PubMed